Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2018-03-27
Original SEC Filing: Click here

---

Webplus: SVA/20180327/6-K/2_EX-99.1/000.htm SEC Original: tv489630_ex99-1.htm
Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction BEIJING, March 27, 2018 /PRNewswire/ — Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that on March 26, 2018, it entered into Amendment No. 1 to the Amalgamation Agreement (the “Amendment”) to amend the Amalgamation Agreement, dated as of

---

---

Webplus: SVA/20180327/6-K/3_EX-99.2/000.htm SEC Original: tv489630_ex99-2.htm
EXECUTION VERSION AMENDMENT NO. 1 TO THE AMALGAMATION AGREEMENT Amendment Parent Amalgamation Sub Company Party Parties AMENDMENT NO. 1 TO AMALGAMATION AGREEMENT (this “ Amalgamation Agreement Amalgamation WHEREAS, the Parties have entered into that certain Amalgamation Agreement, dated as of June 26, 2017 (the “ WHEREAS, the Parties desire to amend the Amalgamation Agreement so as to extend the Termination

---

---

Webplus: SVA/20180327/6-K/1/000.htm SEC Original: tv489630_6k.htm

---

Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2018-03-27CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD, HAIDIAN DISTRICT
BEIJING 100085